The dismal prognosis for patients harboring intracranial gliomas has prompted an intensive search for effective treatment alternatives such as immunotherapy. Our increased knowledge in basic immunology, glioma immunobiology, and molecular biology may lead to the development of effective, rational immunotherapy approaches.
Methods
The authors reviewed the literature on glioma immunology, the status of tumor vaccine therapy and on novel techniques to monitor the tumor-specific immune response.
Results
Experimental conditions currently exist whereby potent antitumor cell-mediated immune responses can be generated. However, clinically, no therapeutic regimen has proven effective. Obstacles to establishing an effective immunotherapy regimen are the lack of a well-defined glioma-specific antigen, the heterogeneity of tumor cells in gliomas, and the modulating effect of the glioma itself on the immune system. Unique strategies to overcome these barriers are being developed.
Conclusions
Novel strategies to generate an anti-glioma immune response through use of dendritic cell vaccination, directed cytokine delivery, gene-based immunotherapy, and reversal of tumor-induced immunosuppression are promising. These strategies carry the potential of overcoming the resistance of gliomas to immunotherapeutic manipulation and, undoubtedly, will become a part of our future therapeutic armamentarium.
References
1.
LeglerJ.M., RiesL.A., SmithM.A.. Cancer surveillance series [corrected]: brain and other central nervous system cancers. Recent trends in incidence and mortality.J Natl Cancer Inst.1999; 91: 1382–1390.
2.
SurawiczT.S., DavisF., FreelsS.. Brain tumor survival: results from the National Cancer Data Base.J Neurooncol.1998; 40: 151–160.
3.
PalmaL., Di LorenzoN., GuidettiB.. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases.J Neurosurg.1978; 49: 854–861.
4.
RidleyA., CavanaghJ.B.. Lymphocytic infiltration in gliomas: evidence of possible host resistance.Brain.1971; 94: 117–124.
5.
BrooksW.H., MarkesberyW.R., GuptaG.D.. Relationship of lymphocyte invasion and survival of brain tumor patients.Ann Neurol.1978; 4: 219–224.
6.
GimmiC.D., FreemanG.J., GribbenJ.G.. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.Proc Natl Acad Sci U S A.1993; 90: 6586–6590.
7.
KagiD., VignauxF., LedermannB.. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.Science.1994; 265: 528–530.
8.
SampsonJ.H., ArcherG.E., AshleyD.M.. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged”central nervous system.Proc Natl Acad Sci U S A.1996; 93: 10399–10404.
9.
HolladayF.P., HeitzT., WoodG.W.. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.J Neurosurg.1992; 77: 757–762.
10.
ChiD.D., MerchantR.E., RandR.. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.Am J Pathol.1997; 150: 2143–2152.
11.
KurpadS.N., ZhaoX.G., WikstrandC.J.. Tumor antigens in astrocytic gliomas.Glia.1995; 15: 244–256.
12.
SampsonJ.H., CrottyL.E., LeeS.. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.Proc Natl Acad Sci U S A.2000; 97: 7503–7508.
13.
McLendonR.E., WikstrandC.J., MatthewsM.R.. Glioma-associated antigen expression in oligodendroglial neoplasms: tenascin and epidermal growth factor receptor.J Histochem Cytochem.2000; 48: 1103–1110.
14.
AshleyD.M., SampsonJ.H., ArcherG.E.. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.J Neuroimmunol.1997; 78: 34–46.
15.
HolladayF.P., HeitzT., ChenY.L.. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes.Neurosurgery.1992; 31: 528–533.
16.
ReardonD.A., AkabaniG., ColemanR.E.. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.J Clin Oncol.2002; 20: 1389–1397.
17.
RivaP., FranceschiG., FrattarelliM.. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma: phase I and II study.Acta Oncol.1999; 38: 351–359.
18.
ParneyI.F., Farr-JonesM.A., ChangL.J.. Human glioma immunobiology in vitro: implications for immunogene therapy.Neurosurgery.2000; 46: 1169–1178.
19.
WellerM., FreiK., GroscurthP.. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: induction and modulation of sensitivity by cytokines.J Clin Invest.1994; 94: 954–964.
20.
LiuY., NgK., LilleheiK.O.. Time course analysis and modulating effects of established brain tumor on active-specific immunotherapy.Neurosurg Focus.2000; 9: 1–9.
21.
RossiM.L., HughesJ.T., EsiriM.M.. Immunohistological study of mononuclear cell infiltrate in malignant gliomas.Acta Neuropathol (Berl.).1987; 74: 269–277.
22.
BurgerP.C., VogelF.S., GreenS.B.. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications.Cancer.1985; 56: 1106–1111.
23.
BrooksW.H., NetskyM.G., NormansellD.E.. Depressed cell-mediated immunity in patients with primary intracranial tumors: characterization of a humoral immunosuppressive factor.J Exp Med.1972; 136: 1631–1647.
24.
MahaleyM.S.Jr., BrooksW.H., RoszmanT.L.. Immunobiology of primary intracranial tumors, part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.J Neurosurg.1977; 46: 467–476.
25.
BodmerS., StrommerK., FreiK.. Immunosuppression and transforming growth factor-beta in glioblastoma: preferential production of transforming growth factor-beta 2.J Immunol.1989; 143: 3222–3229.
26.
BrooksW.H., LattaR.B., MahaleyM.S.. Immunobiology of primary intracranial tumors, part 5: correlation of a lymphocyte index and clinical status.J Neurosurg.1981; 54: 331–337.
27.
RoszmanT., ElliottL., BrooksW.. Modulation of T-cell function by gliomas.Immunol Today.1991; 12: 370–374.
28.
ElliottL.H., BrooksW.H., RoszmanT.L.. Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas.J Neurosurg.1987; 67: 231–236.
29.
MaxwellM., GalanopoulosT., Neville-GoldenJ.. Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance.J Neurosurg.1992; 76: 799–804.
30.
FontanaA., HengartnerH., de TriboletN.. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.J Immunol.1984; 132: 1837–1844.
31.
KuppnerM.C., HamouM.F., SawamuraY.. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.J Neurosurg.1989; 71: 211–217.
32.
OlofssonA., MiyazonoK., KanzakiT.. Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line: identification of small and different forms of large latent complexes.J Biol Chem.1992; 267: 19482–19488.
33.
HuberD., PhilippJ., FontanaA.. Protease inhibitors interfere with the transforming growth factor-beta- dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression.J Immunol.1992; 148: 277–284.
34.
KehrlJ.H., RobertsA.B., WakefieldL.M.. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.J Immunol.1986; 137: 3855–3860.
35.
KehrlJ.H., WakefieldL.M., RobertsA.B.. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.J Exp Med.1986; 163: 1037–1050.
36.
RangesG.E., FigariI.S., EspevikT.. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.J Exp Med.1987; 166: 991–998.
37.
RookA.H., KehrlJ.H., WakefieldL.M.. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.J Immunol.1986; 136: 3916–3920.
38.
KuppnerM.C., HamouM.F., BodmerS.. The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells.Int J Cancer.1988; 42: 562–567.
39.
MiescherS., WhitesideT.L., de TriboletN.. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers.J Neurosurg.1988; 68: 438–448.
40.
MiescherS., WhitesideT.L., CarrelS.. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.J Immunol.1986; 136: 1899–1907.
41.
ZuberP., KuppnerM.C., de TriboletN.. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells.Eur J Immunol.1988; 18: 1623–1626.
42.
ResnicoffM., SellC., RubiniM.. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors.Cancer Res.1994; 54: 2218–2222.
43.
JensenR.L.. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review.Surg Neurol.1998; 49: 189–195.
44.
KuppnerM.C., SawamuraY., HamouM.F.. Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes.J Neurosurg.1990; 72: 619–625.
45.
HishiiM., NittaT., IshidaH.. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.Neurosurgery.1995; 37: 1160–1167.
46.
HuettnerC., CzubS., KerkauS.. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro.Anticancer Res.1997; 17: 3217–3224.
47.
BermanR.M., SuzukiT., TaharaH.. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.J Immunol.1996; 157: 231–238.
48.
Wojtowicz-PragaS.. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.J Immunother.1997; 20: 165–177.
49.
FebvreH., MaunouryR., ConstansJ.P.. Delayed hypersensitivity reactions in patients bearing malignant brain tumors with human tumor cell lines grown in vitro [in French].Int J Cancer.1972; 10: 221–232.
50.
MahaleyM.S.Jr., GillespieG.Y., GillespieR.P.. Immunobiology of primary intracranial tumors, part 8: serological responses to active immunization of patients with anaplastic gliomas.J Neurosurg.1983; 59: 208–216.
51.
MahaleyM.S.Jr., BignerD.D., DudkaL.F.. Immunobiology of primary intracranial tumors, part 7: active immunization of patients with anaplastic human glioma cells: a pilot study.J Neurosurg.1983; 59: 201–207.
52.
BloomH.J., PeckhamM.J., RichardsonA.E.. Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy.Br J Cancer.1973; 27: 253–267.
53.
LilleheiK.O., MitchellD.H., JohnsonS.D.. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.Neurosurgery.1991; 28: 16–23.
54.
LotzeM.T.. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer.Ann Surg.1997; 226: 1–5.
55.
SiesjoP., VisseE., SjogrenH.O.. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.J Immunother Emphasis Tumor Immunol.1996; 19: 334–345.
56.
YuJ.S., WheelerC.J., ZeltzerP.M.. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.Cancer Res.2001; 61: 842–847.
57.
OkadaH., TaharaH., ShurinM.R.. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.Int J Cancer.1998; 78: 196–201.
58.
LiauL.M., BlackK.L., PrinsR.M.. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.J Neurosurg.1999; 90: 1115–1124.
59.
YamanakaR., ZulloS.A., TanakaR.. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.J Neurosurg.2001; 94: 474–481.
60.
AkasakiY., KikuchiT., HommaS.. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.J Immunother.2001; 24: 106–113.
61.
LiauL.M., BlackK.L., MartinN.. Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides: case report.Neurosurg Focus.2000; 9: 1–5.
62.
KikuchiT., AkasakiY., IrieM.. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.Cancer Immunol Immunother.2001; 50: 337–344.
63.
GrabbeS., BeissertS., SchwarzT.. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?Immunol Today.1995; 16: 117–121.
64.
AshleyD.M., SampsonJ.H., ArcherG.E.. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.J Neuroimmunol.1997; 78: 34–46.
65.
FakhraiH., DorigoO., ShawlerD.L.. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.Proc Natl Acad Sci U S A.1996; 93: 2909–2914.
66.
YuJ.S., WeiM.X., ChioccaE.A.. Treatment of glioma by engineered interleukin 4-secreting cells.Cancer Res.1993; 53: 3125–3128.
67.
TsengS.H., HwangL.H., LinS.M.. Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines.J Immunother.1997; 20: 334–342.
68.
SampsonJ.H., AshleyD.M., ArcherG.E.. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.Neurosurgery.1997; 41: 1365–1373.
69.
LiuY., EhteshamM., SamotoK.. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma.Cancer Gene Ther.2002; 9: 9–15.
70.
ParkerJ.N., GillespieG.Y., LoveC.E.. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.Proc Natl Acad Sci U S A.2000; 97: 2208–2213.
71.
AndreanskyS., HeB., van CottJ.. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.Gene Ther.1998; 5: 121–130.
72.
JeanW.C., SpellmanS.R., WallenfriedmanM.A.. Interleukin-12-based immunotherapy against rat 9L glioma.Neurosurgery.1998; 42: 850–857.
73.
WallenfriedmanM.A., ConradJ.A., DelaBarreL.. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.J Neurosurg.1999; 90: 1064–1071.
74.
GriffittW., GlickR.P., LichtorT.. Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system.Neurosurgery.1998; 42: 335–340.
75.
GlickR.P., LichtorT., KimT.S.. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo.Neurosurgery.1995; 36: 548–555.
76.
SobolR.E., FakhraiH., ShawlerD.. Interleukin-2 gene therapy in a patient with glioblastoma.Gene Ther.1995; 2: 164–167.
77.
SchneiderT., GerhardsR., KirchesE.. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme.J Neurooncol.2001; 53: 39–46.
78.
LilleheiK.O., LiuY., KongQ.. Current perspectives in immunotherapy.Ann Thorac Surg.1999; 68: S28–S33.
79.
GorelikL., FlavellR.A.. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.Nat Med.2001; 7: 1118–1122.
80.
RuffiniP.A., RivoltiniL., SilvaniA.. Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.Cancer Immunol Immunother.1993; 36: 409–416.
81.
SatohE., NaganumaH., SasakiA.. Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells.J Neurooncol.1997; 33: 195–200.
82.
SchmittelA., KeilholzU., ThielE.. Quantification of tumor-specific T lymphocytes with the ELISPOT assay.J Immunother.2000; 23: 289–295.
83.
SpellerS.A., WarrenA.P.. Ex vivo detection and enumeration of human antigen-specific CD8+ T lymphocytes using antigen delivery by a recombinant vaccinia expression vector and intracellular cytokine staining.J Immunol Methods.2002; 262: 167–180.
84.
NomuraL.E., WalkerJ.M., MaeckerH.T.. Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells.Cytometry.2000; 40: 60–68.
85.
SuniM.A., PickerL.J., MainoV.C.. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry.J Immunol Methods.1998; 212: 89–98.
86.
AltmanJ.D., MossP.A., GoulderP.J.. Phenotypic analysis of antigen-specific T lymphocytes.Science.1996; 274: 94–96.
87.
HeX.S., RehermannB., Lopez-LabradorF.X.. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers.Proc Natl Acad Sci U S A.1999; 96: 5692–5697.
88.
HempelD.M., SmithK.A., ClaussenK.A.. Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR.J Immunol Methods.2002; 259: 129–138.
89.
KammulaU.S., MarincolaF.M., RosenbergS.A.. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.J Natl Cancer Inst.2000; 92: 1336–1344.
